Mild Clostridium difficile infection (CDI; stool frequency <four-times daily; no signs of severe colitis), clearly induced by the use of antibiotics, may be treated by stopping the inducing ...

Mild Clostridium difficile infection (CDI; stool frequency <four-times daily; no signs of severe colitis), clearly induced by the use of antibiotics, may be treated by stopping the inducing ...

Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If ...

LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for ...

LAVAL, QC - Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a pharmaceutical company with a market capitalization of $2.81 billion and impressive revenue growth of 10.91% over the last twelve months ...

EXL-01 is under development for the treatment of gastric cancer, hepatocellular cancer, non-small cell lung cancer, Clostridium difficile infection and ulcerative colitis. It is a microbiome based ...

Clostridium difficile is a Gram-positive spore-forming bacteria that is a normal component of the colon flora in humans. It can cause antibiotic-associated diarrhea (ADD) when competing bacteria ...

Video content above is prompted by the following: What are the main unmet needs for recurrent C difficile infections and how do you see the field evolving in the future?

Video content above is prompted by the following: What are the common comorbidities seen with recurrent C difficile infections and how can they alter the treatment of the patient?